Ecopipam has been used in trials studying the treatment of Tourette's Syndrome, Lesch-Nyhan Disease, Pathological Gambling, and Self-injurious Behavior.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam. |
| Hydrocodone | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam. |
| Magnesium sulfate | The therapeutic efficacy of Ecopipam can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Ecopipam may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ecopipam. |
| Mirtazapine | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ecopipam. |
| Orphenadrine | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ecopipam. |
| Rotigotine | Ecopipam may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Ecopipam. |
| Sodium oxybate | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam. |
| Thalidomide | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Ecopipam may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Ecopipam is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Ecopipam is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Ecopipam. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Ecopipam. |
| Sulpiride | Ecopipam may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Ecopipam. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Ecopipam. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Ecopipam. |
| Mequitazine | Ecopipam may increase the arrhythmogenic activities of Mequitazine. |
| Ethanol | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Ecopipam may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam. |
| Zimelidine | The risk or severity of adverse effects can be increased when Ecopipam is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Ecopipam is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Ecopipam is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Ecopipam is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Ecopipam is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Ecopipam is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Ecopipam is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Ecopipam is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Ecopipam is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Ecopipam is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Ecopipam is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Ecopipam is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Ecopipam is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Ecopipam is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ecopipam. |
| Indalpine | The risk or severity of adverse effects can be increased when Ecopipam is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Ecopipam is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Ecopipam is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Ecopipam. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Ecopipam. |
| Zopiclone | The risk or severity of adverse effects can be increased when Ecopipam is combined with Zopiclone. |
| Eletriptan | The risk or severity of adverse effects can be increased when Eletriptan is combined with Ecopipam. |
| Cabergoline | The risk or severity of adverse effects can be increased when Cabergoline is combined with Ecopipam. |
| Zolmitriptan | The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ecopipam. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Ecopipam. |
| Dextromethorphan | The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ecopipam. |
| Mazindol | The risk or severity of adverse effects can be increased when Mazindol is combined with Ecopipam. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Ecopipam. |
| Sumatriptan | The risk or severity of adverse effects can be increased when Sumatriptan is combined with Ecopipam. |
| Ergotamine | The risk or severity of adverse effects can be increased when Ergotamine is combined with Ecopipam. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Ecopipam. |
| Almotriptan | The risk or severity of adverse effects can be increased when Almotriptan is combined with Ecopipam. |
| Naratriptan | The risk or severity of adverse effects can be increased when Naratriptan is combined with Ecopipam. |
| Rizatriptan | The risk or severity of adverse effects can be increased when Rizatriptan is combined with Ecopipam. |
| Frovatriptan | The risk or severity of adverse effects can be increased when Frovatriptan is combined with Ecopipam. |
| Chlorpheniramine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Ecopipam. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ecopipam. |
| Bromocriptine | The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ecopipam. |
| Ergometrine | The risk or severity of adverse effects can be increased when Ergometrine is combined with Ecopipam. |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Ecopipam. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Ecopipam. |
| Etoperidone | The risk or severity of adverse effects can be increased when Etoperidone is combined with Ecopipam. |
| Lorpiprazole | The risk or severity of adverse effects can be increased when Lorpiprazole is combined with Ecopipam. |
| Amphetamine | Ecopipam may decrease the stimulatory activities of Amphetamine. |
| Phentermine | Ecopipam may decrease the stimulatory activities of Phentermine. |
| Pseudoephedrine | Ecopipam may decrease the stimulatory activities of Pseudoephedrine. |
| Benzphetamine | Ecopipam may decrease the stimulatory activities of Benzphetamine. |
| Diethylpropion | Ecopipam may decrease the stimulatory activities of Diethylpropion. |
| Lisdexamfetamine | Ecopipam may decrease the stimulatory activities of Lisdexamfetamine. |
| Mephentermine | Ecopipam may decrease the stimulatory activities of Mephentermine. |
| MMDA | Ecopipam may decrease the stimulatory activities of MMDA. |
| 2,5-Dimethoxy-4-ethylamphetamine | Ecopipam may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. |
| Chlorphentermine | Ecopipam may decrease the stimulatory activities of Chlorphentermine. |
| Methylenedioxyethamphetamine | Ecopipam may decrease the stimulatory activities of Methylenedioxyethamphetamine. |
| Dextroamphetamine | Ecopipam may decrease the stimulatory activities of Dextroamphetamine. |
| Metamfetamine | Ecopipam may decrease the stimulatory activities of Metamfetamine. |
| Iofetamine I-123 | Ecopipam may decrease the stimulatory activities of Iofetamine I-123. |
| Ritobegron | Ecopipam may decrease the stimulatory activities of Ritobegron. |
| Mephedrone | Ecopipam may decrease the stimulatory activities of Mephedrone. |
| Methoxyphenamine | Ecopipam may decrease the stimulatory activities of Methoxyphenamine. |
| Gepefrine | Ecopipam may decrease the stimulatory activities of Gepefrine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | Ecopipam may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine. |
| Phendimetrazine | Ecopipam may decrease the stimulatory activities of Phendimetrazine. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Ecopipam. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Ecopipam. |